Photodynamic Therapy: How It Works, Clinical Uses & Future

Photodynamic therapy (PDT) relies on three essential components: a photosensitizer, light, and oxygen. The photosensitizer is a chemically inert compound that only becomes active when illuminated. Blue light is used for photodiagnosis, causing the drug to fluoresce and help surgeons differentiate cancerous tissue from normal tissue. For treatment, red light in the 630–690 nm range is chosen because it penetrates tissue most effectively. When the photosensitizer absorbs red photons, it reaches an excited energy state that converts ground‑state oxygen into singlet oxygen, the primary cytotoxic agent that destroys targeted cells.

Clinical Applications and Challenges

PDT is described as a “gentle” way of treating nasty bits of tissue without upsetting all the nice bits. The therapy kills cancer cells while leaving the underlying connective‑tissue scaffold largely untouched, which supports better healing. Unlike radiotherapy or chemotherapy, PDT does not accumulate toxicity and can be repeated at the same site if needed.

The biggest technical hurdle is delivering a threshold amount of light energy to every part of the lesion. Light intensity drops sharply with depth, so clinicians must ensure enough joules per cubic centimeter reach the point farthest from the source. Endoscopes deliver light to the lining of hollow organs such as the esophagus, bladder, and lungs. For solid organs like the pancreas or prostate, multiple needles are inserted under imaging guidance to distribute light throughout the target tissue.

Future Directions

Researchers are exploring PDT’s potential as an immunostimulant. By inducing a localized immune response, the treatment may “vaccinate” patients against future cancer recurrence. Experimental work also suggests that ablating the duodenal lining could help control type 2 diabetes, and PDT is being investigated for infection control, such as eliminating nasal bacteria to prevent post‑surgical joint infections.

Historical Context and Methodology

Early work used aluminum disulfonated phthalocyanine as a photosensitizer and focused on thermal laser ablation to stop bleeding ulcers and to core out esophageal or airway cancers. Over time, the field shifted toward non‑thermal, targeted PDT. Collaboration between University College London (UCL) and the Royal Institution (RI) dates back to the late 1970s, and senior clinicians with a clear interest in the specific clinical problem now lead clinical trials. The speaker emphasizes the need to understand the biology of these techniques before applying them clinically.